Cholesterol Identified as Key Shield in Heat-Resistant Cancer Cells
/in Hyperthermia, Preclinical Research/by MaxAspirin: New Insights Into Its Mechanism of Interaction With Cancer
/in Drug repurposing, Preclinical Research/by MaxZebrafish Embryo miRNAs: A Potential New Approach to Slow or Stop Cancer Spread
/in Not PCa related, Preclinical Research/by MaxSingle-Cell RNA Sequencing Reveals Three Immune Archetypes in Bone Metastases Across Multiple Cancer Types
/in Immunotherapy, mRNA, Preclinical Research/by MaxScientists Uncover Key Protein Driving Cancer Spread to Bone, ASH1L
/in CRISPR, Preclinical Research/by MaxASH1
ACBP: Scientists Identify Key Protein Driving Bone Metastasis, Pointing to New Therapeutic Strategies
/in CRISPR, Preclinical Research/by MaxTargeting the Undruggable: SCORT–Cas13d Nanotherapy Against Metastatic Prostate Cancer
/in CRISPR, Preclinical Research/by MaxUTRxM1-18: mRNA Drug Targeting c-MYC Offers New Hope for Prostate Cancer Patients
/in mRNA, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026